OakChart

Amphastar Pharmaceuticals Inc

AMPHHealthcare·Drug Manufacturers - Specialty & Generic·USA·Small·NASD·Nov 11 • 2:30 PM ET

29.09+0.03 (0.10%)
2026-11-11 20:31 CET
Market cap
1,239.47 USD m
Revenue, TTM
745.79 USD m
Net income, TTM
98.96 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
2.21
P/E
13.15
Compare

Price

AMPH against its 20, 50 and 200-day averages
2050200beat
20.0025.0030.00992K2.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AMPHclose 29.0920-day 26.9850-day 25.75200-day 22.3329.0952w high52w low

6.2% under the 52-week high of 31.00 on 6 Nov 2026. 52-week low 16.65 on 18 May 2026. Last 15 sessions, 25.9% high to low

Profile

AMPH
52-week range, 87% of the way up
16.6531.00

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredients. It operates through Pharmaceutical Products segment. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

IndexRUT
Employees1976
IPOJun 25, 2014
Beta0.93
ATR, 14d1.09
Rel volume0.65
Short float13.75%
Insider own27.35%
Inst own67.85%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.24B
Enterprise Value1.70B
Income98.96M
Sales745.79M
Book/sh19.10
Cash/sh5.46
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees1976
IPOJun 25, 2014

Ratios

P/E13.15
Forward P/E8.68
PEG2.71
P/S1.66
P/B1.52
P/C5.32
P/FCF8.93
EV/EBITDA8.23
EV/Sales2.28
Quick Ratio2.36
Current Ratio3.32
Debt/Eq0.85
LT Debt/Eq0.84
Option/ShortYes / Yes

Earnings

EPS (ttm)2.21
EPS next Y3.35
EPS next Q0.79
EPS this Y-1.60%
EPS next Y4.85%
EPS next 5Y3.20%
EPS past 3/5Y5.29% 134.65%
Sales past 3/5Y12.99% 15.53%
EPS Y/Y TTM-4.26%
Sales Y/Y TTM3.11%
EPS Q/Q139.24%
Sales Q/Q8.22%
EarningsNov 05 AMC
EPS/Sales Surpr.32.77% 5.11%

Ownership

Insider Own27.35%
Insider Trans-0.53%
Inst Own67.85%
Inst Trans-9.86%
ROA5.86%
ROE12.44%
ROIC6.62%
Gross Margin44.74%
Oper. Margin18.74%
Profit Margin13.27%
SMA207.82%
SMA5012.96%
SMA20030.27%
Trades-

Technical

Shs Outstand42.65M
Shs Float30.99M
Short Float13.75%
Short Ratio9.13
Short Interest4.26M
52W High31.00 -6.16%
52W Low16.65 74.77%
Volatility6.15% 3.86%
ATR (14)1.09
RSI (14)67.71
Beta0.93
Rel Volume0.65
Avg Volume466.88K
Volume236,621

Performance

Perf Week3.82%
Perf Month11.67%
Perf Quarter44.15%
Perf Half Y58.79%
Perf YTD8.63%
Perf Year7.11%
Perf 3Y-44.65%
Perf 5Y37.35%
Perf 10Y38.99%
Recom3.14
Target Price24.50
Prev Close29.06
Price29.09
Change %0.10%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 29, 2026DowngradeBBofA SecuritiesNeutral → Underperform$20-31.2%
May 14, 2026DowngradeWWells FargoOverweight → Equal Weight$19-34.7%
May 08, 2026DowngradeNNeedhamBuy → Hold
Apr 21, 2026DowngradeJJefferiesBuy → Hold$22-24.4%
Dec 09, 2025InitiatedBBarclaysEqual Weight$30+3.1%
Aug 12, 2025UpgradeNNeedhamHold → Buy$36+23.8%
May 12, 2025DowngradeJJP MorganOverweight → Neutral$30+3.1%
Feb 04, 2025DowngradePPiper SandlerOverweight → Neutral$66 → $36+23.8%
Nov 22, 2024InitiatedWWells FargoEqual Weight$55+89.1%
Mar 05, 2024InitiatedJJP MorganOverweight$60+106.3%

Peers

Mkt cap
TickerCompanyMkt cap
AMRXAmneal Pharmaceuticals Inc7.60B
ANIPANI Pharmaceuticals Inc1.63B
XERSXeris Biopharma Holdings Inc2.97B
RDYDr. Reddy's Laboratories Ltd ADR12.28B
TEVATeva- Pharmaceutical Industries Ltd50.21B
EBSEmergent Biosolutions Inc312.35M
VTRSViatris Inc24.14B
ALVOAlvotech1.94B
BAXBaxter International Inc13.66B
SPRYARS Pharmaceuticals Inc388.55M

Insider trading

latest 14 of 31
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
PETERS WILLIAM JCFO, EVP & TREASURERNov 04 '26Option Exercise13.0316,000208,480184,707Nov 06 04:17 PM
PETERS WILLIAM JCFO, EVP & TREASURERNov 05 '26Option Exercise17.9911,000197,890179,707Nov 06 04:17 PM
PETERS WILLIAM JCFO, EVP & TREASURERNov 04 '26Sale28.0316,000448,480168,707Nov 06 04:17 PM
PETERS WILLIAM JCFO, EVP & TREASURERNov 05 '26Sale28.9912,631366,189167,076Nov 06 04:17 PM
PETERS WILLIAM JOfficerNov 05 '26Proposed Sale28.9912,631366,189Nov 05 04:05 PM
PETERS WILLIAM JOfficerNov 04 '26Proposed Sale28.0316,000448,480Nov 04 04:09 PM
PETERS WILLIAM JCFO, EVP & TREASURERSep 21 '26Sale25.004,139103,475168,707Sep 23 06:02 PM
PETERS WILLIAM JOfficerSep 21 '26Proposed Sale25.004,139103,475Sep 21 06:37 PM
Zhou RongSENIOR EVP, PRODUCTION CENTERSep 16 '26Option Exercise13.3510,000133,500179,203Sep 17 06:19 PM
Zhou RongSENIOR EVP, PRODUCTION CENTERSep 16 '26Sale23.9410,000239,404169,203Sep 17 06:19 PM
Zhou RongSENIOR EVP, PRODUCTION CENTERSep 02 '26Sale23.633,18775,306169,203Sep 03 07:42 PM
Rong ZhouVice PresidentSep 01 '26Proposed Sale22.0013,187290,114Sep 01 04:25 PM
Floyd PetersenDirectorAug 18 '26Proposed Sale21.0047,101989,121Aug 18 05:56 PM
PRINS RICHARD KDirectorAug 11 '26Sale20.307,973161,85229,625Aug 12 06:14 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
AVUVAvantis U.S. Small Cap Value ETFAUM: 32.39B
DFSVUS Small Cap Value Portfolio ETF Class SharesAUM: 8.52B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
DFATU.S. Targeted Value Portfolio-ETF Class SharesAUM: 14.47B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M

News

latest 14 of 100
  • Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London (PR Newswire)
  • Amphastar Beats Handily On BAQSIMI Repair, But Margin Erosion And IMS Drag Temper The Record Quarter (Earnings Whispers)
  • Amphastar: Q3 Earnings Snapshot (Associated Press)
  • Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 (PR Newswire)
  • Amphastar's Rally Faces A Test As New Launches Race The IMS Warning Letter (Earnings Whispers)
  • Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026 (PR Newswire)
  • Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference (PR Newswire)
  • Amphastar: Q2 Earnings Snapshot (Associated Press)
  • Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 (PR Newswire)
  • Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 (PR Newswire)
  • BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns (Investing.com)
  • Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference (ACCESSWIRE)
  • Amphastar: Q1 Earnings Snapshot (Associated Press) -20.93%
  • Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-051.1400.8590.870207.61197.527
2026Q22026-08-060.9100.6200.686183.9179.927
2026Q12026-05-070.4200.7050.138171.17173.467
2025Q42026-02-260.7300.9030.518183.11188.777
2025Q32025-11-060.9300.8250.364191.84186.226
2025Q22025-08-070.8500.7420.645174.41173.986
2025Q12025-05-070.7400.6870.507170.53172.946
2024Q42025-02-270.9200.9380.740186.52188.766
2024Q32024-11-060.9600.9880.780191.21194.675
2024Q22024-08-070.9400.7720.729182.4170.966
2024Q12024-05-081.0400.7730.815171.84174.656
2023Q42024-02-280.8800.9100.682178.11173.435
2023Q32023-11-081.1500.6950.913180.56174.634
2023Q22023-08-080.6500.5600.492145.71137.274
2023Q12023-05-100.6200.5320.501140.02137.275
2022Q42023-02-280.7300.4000.656135.02127.186

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.3600.3480.981322.36320.83
2020FY0.6400.5930.029349.85342.5
2021FY1.3701.3131.248437.77428.5
2022FY1.9701.6401.743498.99491.21
2023FY3.3203.3562.595644.4639.6
2024FY3.8603.8733.064731.97734.23
2025FY3.2503.4382.030719.89725.56
2026FY-3.198--758.48
2027FY-3.353--792.44
2028FY-3.572--821.7
2029FY-3.450--874
2030FY-3.310--887

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06621195.73183204
2026Q4S2026-11-05600194.74171.8203.8
2026Q4S2026-10-21600194.74171.8203.8
2026Q4S2026-09-12632194.74171.8203.8
2026Q4S2026-08-07633194.74171.8203.8
2026Q4S2026-07-22611196.65184207.8
2026Q4S2026-07-17623196.82184207.8
2026Q4S2026-07-16623196.82184207.84
2026Q4S2026-06-29613196.24184204.32
2026Q4S2026-05-10622197.4184204.32
2026Q4S2026-05-08623197.4184204.32
2026Q4S2026-04-20611197.22184.52203.6
2026Q4S2026-04-17611196.94184.52203.6
2026Q4S2026-02-27611197.17184.52205

Estimate history

EPS, annual0.075-0.1240.9810.0291.2481.7432.5953.0642.0352.213
Period201720182019202020212022202320242025TTM
EPS, quarterly0.780.740.5070.6450.3640.5180.1380.6860.871
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual240.175294.666322.357349.846437.768498.987644.395731.967719.887745.79
Period201720182019202020212022202320242025TTM
Sales, quarterly191.214186.523170.528174.414191.84183.105171.171183.903207.608
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual46.62446.63146.57747.49547.71548.11248.06947.61845.64542.648
Period201720182019202020212022202320242025MRQ
Shares, quarterly48.37347.61847.6746.49146.34945.64544.63742.53242.648
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue745.79719.89731.97644.39498.99437.77349.85322.36294.67
Cost of Goods Sold Incl. D&A412.12378.43370.60300.43260.19249.27216.55199.17193.00
Gross Profit333.67341.45361.37343.97238.80188.50133.29123.19101.67
Selling, General and Administrative Excl. Other193.93201.05155.95144.28131.30118.26122.10123.23110.29
Research and Development76.8771.2461.4363.8964.7149.7057.0860.2652.43
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income139.74140.40205.42199.69107.5070.2311.19-0.04-8.62
Interest Expense26.6025.4830.3427.161.850.890.370.120.24
Unusual Expense-16.00-4.30-5.00-3.20-4.93-15.9613.04-59.90-
Net Income Before Taxes129.57123.62189.76171.36116.0484.144.6460.23-9.93
Income Taxes30.6125.5329.6731.8323.4820.633.5413.72-3.27
Consolidated Net Income98.9698.09159.52137.5491.3963.301.1046.51-6.66
Net Income From Continuing Operations98.9698.09159.52137.5491.3962.121.4048.94-5.74
Net Income98.9698.09159.52137.5491.3962.121.4048.94-5.74
EPS (Recurring)2.021.973.002.551.681.020.210.14-0.12
EPS (Basic, Before Extraordinaries)2.262.103.292.851.881.300.031.04-0.12
EPS (Diluted)2.212.033.062.601.741.250.030.98-0.12
EBITDA206.42203.60262.62241.46136.2496.9936.3721.087.89
Non-Operating Income (Expense)0.444.409.69-4.375.46-1.176.860.49-1.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense23.3721.5519.2515.9914.1113.6414.9612.6313.18
Price To Earnings Ratio13.1313.1312.3524.1518.8318.72827.5719.70-
Price To Sales Ratio1.501.792.645.092.942.652.822.993.13
Gross Margin44.7447.4349.3753.3847.8643.0638.1038.2234.50
Operating Margin18.7419.5028.0630.9921.5416.043.20-0.01-2.93
Net Margin13.2713.6321.7921.3418.3114.190.4015.18-1.95
Shares Outstanding42.6545.6547.6248.0748.1147.7147.5046.5846.63
Market Capitalization1,239.471,239.471,785.262,963.071,354.241,114.41955.31905.43917.35

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue207.61183.90171.17183.10191.84174.41170.53186.52
Cost of Goods Sold Incl. D&A111.8994.29104.68101.2596.8291.9188.45103.16
Gross Profit95.7289.6166.4981.8695.0282.5082.0883.37
Selling, General and Administrative Excl. Other44.9549.8852.8646.2569.7040.3244.7838.22
Research and Development16.1718.3022.9019.5018.7316.0916.9214.86
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income50.7739.7313.6335.6125.3242.1837.2945.14
Interest Expense6.766.666.556.636.286.286.296.42
Unusual Expense-3.00-2.10-2.00-8.900.001.702.90-6.60
Net Income Before Taxes49.0638.5410.0531.9121.5139.3430.8643.96
Income Taxes11.308.203.637.494.168.305.586.00
Consolidated Net Income37.7630.356.4224.4317.3531.0325.2937.96
Net Income From Continuing Operations37.7630.356.4224.4317.3531.0325.2937.96
Net Income37.7630.356.4224.4317.3531.0325.2937.96
EPS (Recurring)0.820.650.110.390.360.670.550.65
EPS (Basic, Before Extraordinaries)0.890.700.140.530.370.660.530.79
EPS (Diluted)0.870.690.140.520.360.640.510.74
EBITDA68.5256.1930.1251.5941.0958.4252.5059.81
Non-Operating Income (Expense)2.053.370.97-5.962.485.132.75-1.36
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.545.607.334.904.975.046.634.45
Price To Earnings Ratio13.1312.129.6311.879.988.339.4612.35
Price To Sales Ratio1.501.221.261.751.761.531.982.60
Gross Margin46.1148.7338.8444.7049.5347.3048.1344.70
Operating Margin24.4621.607.9619.4513.2024.1921.8724.20
Net Margin18.1916.503.7513.349.0417.7914.8320.35
Shares Outstanding42.6542.5344.6445.6546.3546.4947.6747.62
Market Capitalization1,239.47889.79888.801,230.601,239.091,082.311,381.381,785.26

Balance sheet, annual

No statement data.

Cash flow, annual

No statement data.

Balance sheet, quarterly

No statement data.

Cash flow, quarterly

No statement data.

Revenue breakdown

Other2024: 19.15M
Product2024: 712.81M 2025: 719.89M
China2024: 4.34M 2025: 3.18M
France2024: 19.95M 2025: 35.28M
United States2024: 707.68M 2025: 681.42M
Total Pharmaceutical Preparations revenue2024: 731.97M 2025: 719.89M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.75%4.3M31.0M464.41K
2026-10-1514.02%4.3M30.9M471.94K
2026-09-3014.25%4.4M30.9M462.19K
2026-09-1516.16%5.0M30.9M477.89K
2026-08-3116.62%5.1M30.9M489.88K
2026-08-1417.16%5.4M31.4M564.42K
2026-07-3115.66%4.9M31.5M608.57K
2026-07-1512.80%4.2M32.6M610.55K
2026-06-3011.79%3.8M32.6M621.86K
2026-06-1511.65%3.8M32.6M589.35K
2026-05-2911.45%3.7M32.7M621.05K
2026-05-1511.47%3.8M33.0M595.97K
2026-04-3010.82%3.6M33.1M515.98K
2026-04-1512.08%3.9M32.3M492.27K
2026-03-3110.75%3.5M32.8M481.04K
2026-03-1311.40%3.7M32.8M447.52K
2026-02-2711.15%3.7M32.8M384.57K
2026-02-1311.20%3.7M33.2M351.38K
2026-01-3011.57%3.8M33.2M390.31K
2026-01-1511.44%3.8M33.2M403.47K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.5014.5018.600.006.1710.000.000.904-0.3380.008
call15.0012.0016.000.005.0890.000.000.877-0.3340.009
call17.509.5013.500.004.1900.000.000.848-0.3230.011
call20.007.0011.000.003.4130.000.000.813-0.3050.012
call22.504.508.507.022.7150.000.000.770-0.2810.014
call25.002.005.704.231.92920.000.000.714-0.2500.015
call30.000.101.000.440.75253.001.000.477-0.1250.018
call35.000.003.400.151.5811.000.000.260-0.1310.015
put12.500.003.400.007.7240.000.00-0.097-0.3340.008
put15.000.003.400.006.3950.000.00-0.124-0.3290.009
put17.500.003.400.005.3160.000.00-0.154-0.3170.011
put20.000.003.400.404.3951.000.00-0.189-0.2990.012
put22.500.003.400.453.5873.000.00-0.232-0.2760.014
put25.000.003.000.002.7540.000.00-0.297-0.2360.016
put30.000.004.200.002.0510.000.00-0.523-0.1210.018
put35.004.308.000.002.3080.000.00-0.737-0.1260.015

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-05144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-21144Filing for proposed sale of securities under Rule 144.SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-14SCHEDULE 13GSEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-133Initial statement of beneficial ownership of securities2026-07-09SEC
2026-07-138-KCurrent report2026-07-09SEC
2026-07-088-KCurrent report2026-07-02SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-038-KCurrent report2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2024-08-19SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100814.67K2
2026-100000
2026-0900418.18K3
2026-0800345.74K2
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1200363.89K3
2025-1100567.72K3

Institutional holders

Manager% owned
BlackRock, Inc.11.85%
DIMENSIONAL FUND ADVISORS LP5.60%
STATE STREET CORP3.72%
VANGUARD CAPITAL MANAGEMENT LLC3.36%
AMERICAN CENTURY COMPANIES INC2.67%
MARSHALL WACE, LLP2.42%
GEODE CAPITAL MANAGEMENT, LLC2.28%
FULLER & THALER ASSET MANAGEMENT, INC.2.15%
D. E. Shaw & Co., Inc.2.01%
VANGUARD PORTFOLIO MANAGEMENT LLC1.84%

Funds

Fund% owned
Miller Convertible Bond Fund20.41%
Miller Intermediate Bond Fund10.10%
Fidelity Convertible Securities Fund5.01%
iShares Core S&P Small-Cap ETF4.64%
Avantis U.S. Small Cap Value ETF2.68%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.39%
Fidelity Strategic Dividend and Income Fund2.07%
FULLERTHALER BEHAVIORAL SMALL CAP EQUITY2.05%
iShares Russell 2000 ETF1.92%
U.S. SMALL CAP VALUE PORTFOLIO1.35%

OakChart. AMPH. Cached 15 minutes.